CRISPR Therapeutics AG (NASDAQ:CRSP)’s traded shares stood at 3.77 million during the last session, with the company’s beta value hitting 1.81. At the close of trading, the stock’s price was $68.14, to imply an increase of 3.35% or $2.21 in intraday trading. The CRSP share’s 52-week high remains $71.13, putting it -4.39% down since that peak but still an impressive 55.91% since price per share fell to its 52-week low of $30.04. The company has a valuation of $5.88B, with an average of 4.38 million shares in intraday trading volume over the past 10 days and average of 2.95 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for CRISPR Therapeutics AG (CRSP), translating to a mean rating of 1.93. Of 8 analyst(s) looking at the stock, 0 analyst(s) give CRSP a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 6 recommend it as a Buy.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
After registering a 3.35% upside in the last session, CRISPR Therapeutics AG (CRSP) has traded red over the past five days. The 5-day price performance for the stock is 23.58%, and 49.59% over 30 days. With these gigs, the year-to-date price performance is 24.89%. Short interest in CRISPR Therapeutics AG (NASDAQ:CRSP) saw shorts transact 25.54 million shares and set a 7.47 days time to cover.
The extremes give us $65 and $65 for target low and target high price respectively. As such, CRSP has been trading 4.61% off suggested target high and 4.61% from its likely low.
CRSP Dividends
CRISPR Therapeutics AG has its next earnings report out on 2025-May-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
CRISPR Therapeutics AG insiders hold 1.69% of total outstanding shares, with institutional holders owning 76.06% of the shares at 77.37% float percentage. In total, 76.06% institutions holds shares in the company, led by CAPITAL INTERNATIONAL INVESTORS. As of 2024-06-30, the company held over 7.87 million shares (or 9.2619% of shares), all amounting to roughly $424.8 million.
The next major institution holding the largest number of shares is ARK INVESTMENT MANAGEMENT LLC with 7.78 million shares, or about 9.1597% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $420.12 million.
We also have ARK ETF Trust-ARK Innovation ETF and NEW PERSPECTIVE FUND as the top two Mutual Funds with the largest holdings of the CRISPR Therapeutics AG (CRSP) shares. Going by data provided on Jun 30, 2025 , ARK ETF Trust-ARK Innovation ETF holds roughly 7.04 shares. This is just over 8.16% of the total shares, with a market valuation of $479.96 million. Data from the same date shows that the other fund manager holds a little less at 2.15, or 2.49% of the shares, all valued at about 146.25 million.
